<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

T Cell Dysfunction Assays for In Vitro Screening of Immunomodulatory Drug Candidates

T Cell Dysfunction Assays for In Vitro Screening of Immunomodulatory Drug CandidatesReview the latest advances in the recall antigen assay, to provide an optimized system for screening and characterizing immunomodulatory drug candidates, including recapitulating aspects of a suppressed tumor microenvironment (TME).

Why Functional-Based Characterization of Immunomodulatory Drug Candidates is Essential

Identifying a lead immunomodulatory drug candidate is a major responsibility for companies developing immunotherapeutics. Selecting models for target dependent and function-based characterization assays is vital for the identification of lead drug candidates, and there are many in vitro and in vivo platforms available to meet this need.

These platforms are also used for applications such as dose determination and combinatorial effects. As in vitro assays are commonly faster and less involved than in vivo studies, it’s generally recommended to test drug candidates in multiple assay systems.

Since immunotherapeutic drug candidates target various cell lineages and pathways, assays that have flexible readouts are often the most useful. For example, some drug candidates act mainly by modifying T cell activity, whereas others initially impact the myeloid cells.

In this post, I’m focusing on reviewing T cell modifier and dysfunction assays. Across the variety of assays available in this field, they are some challenges to overcome. In particular, in vitro assays that use primary cells face issues including a lack of standardization across research sites.

Here, we’ll look at peripheral mononuclear cell (PBMC)-based in vitro assays for functional characterization of immunomodulatory (including anti-inflammatory) candidate drugs, and discuss the new advancements which are addressing the challenges associated with these techniques.

Challenges with PBMC-Based Recall Antigen Assays

The core of these assays is the recall antigen assay using whole PBMC from characterized donors. PBMC stimulated with mitogens or general (polyclonal) stimuli provide a functional readout for screening and characterization of immunomodulatory drug candidates.

PMBC-based assays have been used in the development of currently approved immune checkpoint inhibitors, to demonstrate the functional activity of their clones or lead drugs. However, these assays lack a standardized protocol, often suffer from poor reproducibility, and have low signal-to-noise ratio.

Advancements in PBMC-Based Recall Antigen Assays

New advancements within this assay are now available to overcome these issues and provide a controlled and simple system for screening and characterizing drug candidates. Several parameters of the assay have been changed to optimize outputs, such as pre-screening and selecting “responder” donors, as well as optimizing assay conditions including:

  • Selection of the right donors
  • The stimulation stage
  • The plate polymer
  • Culture media
  • Interleukins/milieu of cytokines
  • Improving readout using a MHC tetramer guided platform

Readouts have also been enhanced to include cytokines and measurement of expanded recall antigen-specific T cell clonotypes in using a cocktail of MHC tetramers.

Advantages of Optimized PBMC-Based Recall Antigen Assays

There are many advantages of optimized and validated PBMC-based recall antigen assays. PBMCs are considered a surrogate of the innate and adaptive immunity of hosts, and to this end PBMCs provide essential cell lineages as a physiologically relevant assay system. Optimized assays use various cell lineages and subsets such as CD4+ T cells, CD8+ T cells, B cells, monocytes, dendritic cells, NK cells, and regulatory T cells.

The assay also has the co-inhibitory and co-stimulatory pathways and is amenable to many readouts:

  • Using flow cytometry including intracellular staining
  • ELISA using supernatant
  • RNAseq
  • Analysis of different cell lineages or antigen-specific T cells
  • Assaying biomarkers cytokines, monokines, co-stimulatory / co-inhibitory molecules at various cell levels
  • Polyclonal or antigen specific CD8 or CD4 T cell clonotypes

Adenosine-Based Recall Assay for Drug Screening

The assays mentioned above are extremely useful, but they all lack one main point - the suppressed TME. The happiest antitumor T cell stays active until it meets the TME. This means that the most active T cell potentiating agents must be tested in a TME-like culture.

To fulfill this need, new assays are now being developed, based around major factors inducing TME-mediated T cell suppression. Adenosine is expressed in almost all tumor deposits and produces robust, and highly reproducible, T cell suppression in vitro without affecting cell viability. Adenosine exerts its powerful endogenous inhibitory effects on inflammatory processes via interaction with A1, A2A, A2B and A3 adenosine receptors.

A new adenosine/recall antigen-based in vitro assay system has now been developed and validated for functional characterization of many different classes of therapeutic candidates, providing a variety of readouts. The addition of adenosine improves the recall antigen assay by recapitulating the suppressed TME, and can be used to answer many drug development questions/problems, including:

  • Does the drug candidate reverse adenosine induced suppression?
  • Can drug candidates withstand the suppressed microenvironment of tumor deposit?

The new assay also provides a screening platform for non-steroidal anti-inflammatory drug candidates, and to explore the off-targeting impact of drugs on adaptive immunity.

Conclusion

The recall antigen assay is arguably one the most physiologically relevant assays to identify the next generation of immunomodulatory drug candidates. This is due to the assay using naturally induced memory T cells and utilizing a controlled antigenic system.

However, since it uses primary cells, the assay presents many challenges including a lack of standardization, reproducibility, and supply. Improved recall antigen assays have now been developed, by addressing each step of the assay and its readouts, and through spiking with adenosine to recapitulate some aspect of suppressed TME.


Related Posts